Detail akcie Exact Sciences online

Business Summary: Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Exact Sciences Corp revenues increased 20% to $2.5B. Net loss decreased 67% to $204.1M. Revenues reflect Commercial segment increase of 27% to $1.17B, Medicare Parts B & C segment increase of 20% to $890.1M, United States (Country) segment increase of 19% to $2.35B, Outside of united states segment increase of 30% to $153.3M.